2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149050
    Viral polymerase-IN-1 hydrochloride
    		Inhibitor
    Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC90 values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against SARS-CoV-2 infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells.
    Viral polymerase-IN-1 hydrochloride
  • HY-168917
    9-AMN
    		Inhibitor
    9-AMN is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC50 of 4.55 µM and 4.15 µM. 9-AMN inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC50 of 1.04 µM and 2.35 µM.
    9-AMN
  • HY-149256
    PLpro/RBD-IN-1
    		Inhibitor
    PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC50s of 7.197 μM and 8.673 μM, respectively.
    PLpro/RBD-IN-1
  • HY-174373
    SARS-CoV-2-IN-113
    		Inhibitor
    SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against SARS-CoV-2 infection with an IC50 of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113 has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV-2.
    SARS-CoV-2-IN-113
  • HY-156337
    SARS-CoV-2-IN-63
    		Inhibitor
    SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 1.99 μM and 1.92 μM, respectively.
    SARS-CoV-2-IN-63
  • HY-P10689
    NQK-A8 peptide
    NQK-A8 peptide is an immunodominant peptide of seasonal coronaviruses HKU1-CoV and OC43-CoV.
    NQK-A8 peptide
  • HY-106560
    Proglumetacin
    		Inhibitor
    Proglumetacin is an orally active and potent cyclo-oxygenase inhibitor. Proglumetacin can inhibits SARS-CoV Mpro (main protease of the SARS-CoV-2), with an AC50 of 8.9 μM (activity concentration at half maximal activity). Proglumetacin has anti-inflammatory activity, can be used for inflammation (such as Rheumatoid arthritis, and Allergic air pouch inflammation) research[1][2][3].
    Proglumetacin
  • HY-158073
    ML2006a4
    		Inhibitor
    ML2006a4 is an orally active inhibitor for SARS-CoV-2 main protease (Mpro) with IC50 in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level
    ML2006a4
  • HY-175344
    TMP1
    		Inhibitor
    TMP1 is an orally active bispecific inhibitor of M pro (IC50 = 312.5 nM)/TMPRSS2 (IC50 = 1.28 μM, KD = 10.10 μM). TMP1 exhibits broad protection against different SARS-CoV-2 variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection by SARS-CoV-2 escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research.
    TMP1
  • HY-155016
    SARS-CoV-2-IN-46
    		Inhibitor 99.77%
    SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC50 of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research.
    SARS-CoV-2-IN-46
  • HY-163912
    JZD-07
    		Inhibitor
    JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of SARS-CoV-2 infection.
    JZD-07
  • HY-163908
    SARS-CoV-2-IN-94
    		Inhibitor
    SARS-CoV-2-IN-94 (Compound 6) exhibits antiviral activity against COVID-19 virus by targeting 6VSB protein.
    SARS-CoV-2-IN-94
  • HY-162956
    SARS-CoV-2-IN-97
    		Inhibitor
    SARS-CoV-2-IN-97 (Compound CO-01) is an inhibitor for SARS-CoV-2 Nsp15 endoribonuclease with an IC50 of 53.5 μM. SARS-CoV-2-IN-97 exhibits low cytotoxicity in A549-AT cell with IC50 of 134 μM.
    SARS-CoV-2-IN-97
  • HY-161244
    FGA145
    		Inhibitor
    FGA145 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 3.71 μM, 9.82 μM and 53 nM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA145 reveals a multitarget effects in the antiviral activity.
    FGA145
  • HY-112894
    ZG-10
    		Inhibitor
    ZG-10 (JNK-IN-2) is a JNK inhibitor, with IC50 values of 809 nM, 1140 nM and 709 nM for JNK1, JNK2, and JNK3, respectively. ZG-10 (JNK-IN-2) is a potential anti-SARS-CoV-2 agent.
    ZG-10
  • HY-126420
    Kansuinine B
    		Inhibitor ≥99.0%
    Kansuinine B inhibits IL-6-induced Stat3 activation. Kansuinine B possesses anti-viral activity and could be used in the study for COVID-19.
    Kansuinine B
  • HY-149656
    D1N52
    		Inhibitor
    D1N52 is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.53 μM.
    D1N52
  • HY-149267
    STING agonist-30
    		Inhibitor
    STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    STING agonist-30
  • HY-110066R
    (Z)-Guggulsterone (Standard)
    		Inhibitor
    (Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis. (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection.
    (Z)-Guggulsterone (Standard)
  • HY-144062
    INSCoV-614(1B)
    INSCoV-614(1B) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).
    INSCoV-614(1B)
Cat. No. Product Name / Synonyms Species Source